Docbot, Inc. is an artificial intelligence technology company focusing on gastrointestinal (GI) disease. Docbot’s products are built on the UltivisionAI software platform for real-time image analysis, automated reporting, and analytic tools to improve patient care and clinical workflows.
Our mission is to provide the most powerful AI-assisted image analysis solutions to revolutionize GI care.
Our mission is to provide the most powerful AI-assisted image analysis solutions to revolutionize GI care.
Location: United States, California, Irvine
Employees: 1-10
Total raised: $4M
Founded date: 2014
Investors 2
| Date | Name | Website |
| - | SAV (Scale... | sav.vc |
| - | Boutique V... | boutiquevc... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.05.2021 | - | $4M | - |
Mentions in press and media 5
| Date | Title | Description |
| 07.08.2021 | Venture Cash Is Pouring Into AI that Can Diagnose Diseases. Doctors Aren’t Sure They Can Trust It. | Medical imaging AI, which can help diagnose health problems doctors don't always see, is only getting more sophisticated—and more lucrative. Just last month, Tel Aviv-based Aidoc raised $65 million for its AI-powered medical imaging platfor... |
| 28.05.2021 | StartUPDATES: New developments from healthcare startups | Blue Therapeutics has released the second part of a receptor-interactomics™ concept paper series, “Innate Proximity: inherent physicality of receptor interactions” by Ajay Yekkirala, CSO and co-founder of Blue Therapeutics. As part of Blue’... |
| 25.05.2021 | Docbot Raises $4M For AI Diagnosis Tools | Irvine-based Docbot, a startup developing artificial intelligenec tools for diagnosing gastrointestinal (GI) disease, has raised $4M in a Series A funding round, according to the company. The funding was led by Khosla Ventures, and also inc... |
| 24.05.2021 | Docbot, which uses AI to detect gastrointestinal disease, raises $4M as it gets a new CEO | The company has appointed Andrew Ritter, the co-founder and former CEO of Ritter Pharmaceuticals Artificial intelligence is transforming the healthcare industry, as the global market for AI is expected to grow from $4.9 billion in 2020 to $... |
| - | StartUPDATES: New developments from healthcare startups | Blue Therapeutics has released the second part of a receptor-interactomics™ concept paper series, “Innate Proximity: inherent physicality of receptor interactions” by Ajay Yekkirala, CSO and co-founder of Blue Therapeutics. As part of Blue’... |